Table 1 Demographics and disease characteristics of the subject who received at least one dose of obinutuzumab
Variable | CLL (n = 12) | DLBCL (n = 23) | FL (n = 13) | Overall (n = 48) |
|---|---|---|---|---|
Age at baseline (years) | ||||
Mean (sd) | 60.7 (12.0) | 53.3 (15.8) | 55.1 (8.8) | 55.6 (13.4) |
Gender [n (%)] | ||||
Male | 7 (58.3) | 11 (47.8) | 8 (61.5) | 26 (54.2) |
Female | 5 (41.7) | 12 (52.2) | 5 (38.5) | 22 (45.8) |
Weight (kg) | ||||
Mean (sd) | 60.83 (11.44) | 62.33 (9.86) | 64.27 (12.49) | 62.48 (10.85) |
Height (cm) | ||||
Mean (sd) | 161.0 (5.0) | 164.1 (7.1) | 166.3 (10.7) | 163.9 (7.9) |
ECOG at baseline [n (%)] | ||||
0 | 2 (16.7) | 8 (34.8) | 8 (61.5) | 18 (37.5) |
1 | 10 (83.3) | 15 (65.2) | 5 (38.5) | 30 (62.5) |
Ann Arbor stage at diagnosisa [n (%)] | ||||
I | N/A | 0 | 2 (15.4) | 2 (5.6) |
II | N/A | 4 (17.4) | 0 | 4 (11.1) |
III | N/A | 8 (34.8) | 5 (38.5) | 13 (36.1) |
IV | N/A | 7 (30.4) | 3 (23.1) | 10 (27.8) |
Missing | N/A | 4 (17.4) | 3 (23.1) | 7 (19.4) |
Binet stagea [n (%)] | ||||
Stage A | 1 (8.3) | N/A | N/A | 1 (8.3) |
Stage B | 6 (50.0) | N/A | N/A | 6 (50.0) |
Stage C | 2 (16.7) | N/A | N/A | 2 (16.7) |
Unknown | 3 (25.0) | N/A | N/A | 3 (25.0) |
Number of previous lines of treatment | ||||
Median | 2.0 | 2.0 | 3.0 | 2.0 |
Minimum–maximum | 1–7 | 1–11 | 1–6 | 1–11 |
Best response of prior treatment [n (%)] | ||||
CR | 1 (8.3) | 9 (39.1) | 2 (15.4) | 12 (25.0) |
PR | 8 (66.7) | 9 (39.1) | 7 (53.8) | 24 (50.0) |
SD | 1 (8.3) | 2 (8.7) | 0 | 3 (6.3) |
PD | 0 | 2 (8.7) | 0 | 2 (4.2) |
Missing | 2 (16.7) | 1 (4.3) | 4 (30.8) | 7 (14.6) |
Duration of best response | ||||
n | 6 | 18 | 7 | 31 |
Mean (sd) (days) | 355.2 (604.2) | 152.5 (119.2) | 159.4 (136.4) | 193.3 (281.3) |